Effect of 5-alpha-reductase inhibition on sex-hormone-binding globulin in elderly men

Horm Res. 1994;41(5-6):215-7. doi: 10.1159/000183926.

Abstract

In this study we examined the possibility that chronic reduction in serum dihydrotestosterone (DHT) attained by pharmacologic inhibition of 5 alpha-reductase modulates serum sex-hormone-binding globulin (SHBG) levels in elderly men. Twenty-one men, ages 58-79 years (mean 66) with benign prostatic hypertrophy were treated with the 5 alpha-reductase inhibitor finasteride (5 mg daily) for 12 months. Serum DHT declined by 80% (p < 0.001) and total testosterone rose by 14% (p < 0.05). Serum SHBG concentration remained unchanged (44.1 +/- 4.5 vs 45.2 +/- 5.7 nmol/l for pre- and post-therapy levels, respectively). Thus, the conversion of testosterone to DHT is not required to maintain the androgenic effect on serum SHBG concentration in elderly men.

MeSH terms

  • Aged
  • Cholestenone 5 alpha-Reductase
  • Dihydrotestosterone / blood
  • Finasteride / pharmacology*
  • Finasteride / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Oxidoreductases / antagonists & inhibitors*
  • Oxidoreductases / blood
  • Prostatic Hyperplasia / drug therapy
  • Radioimmunoassay
  • Sex Hormone-Binding Globulin / analysis*
  • Testosterone / blood

Substances

  • Sex Hormone-Binding Globulin
  • Dihydrotestosterone
  • Testosterone
  • Finasteride
  • Oxidoreductases
  • Cholestenone 5 alpha-Reductase